Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
How to buy Intercept Pharmaceuticals stock
Learn how to easily invest in Intercept Pharmaceuticals stock.
Intercept Pharmaceuticals is a biotechnology business based in the US. Intercept Pharmaceuticals shares (ICPT) are listed on the NASDAQ and all prices are listed in US Dollars. Intercept Pharmaceuticals employs 437 staff and has a trailing 12-month revenue of around $379.8 million.
How to buy Intercept Pharmaceuticals stock
- Open a stock trading account. Use our comparison table or choose from our Top Picks.
- Confirm your payment details. Fund your account with a bank transfer, debit card or credit card and take advantage of any signup bonuses.
- Search for the stock by name or ticker symbol – ICPT. It's that simple.
- Trade stocks for $0 and no annual fee
- Start trading with a $0 minimum deposit
- Get up to $1,000 when you fund a new account within 30 days
- Get free stock upon signup
- Earn 4% interest on uninvested cash with Robinhood Gold
- Get 1% match on contributions to a Robinhood IRA
- $0 commissions on stocks and ETFs
- $0 closing commissions on stock and ETF options
- Get $200 in US stocks when you open and fund an account with min. $2,000 for 3+ mos.
Intercept Pharmaceuticals stock price (NASDAQ: ICPT)Use our graph to track the performance of ICPT stocks over time.
Intercept Pharmaceuticals shares at a glance
|Latest market close||$18.40|
|52-week range||$10.81 - $21.25|
|50-day moving average||$14.48|
|200-day moving average||$15.37|
|Wall St. target price||$22.71|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-2.20|
Buy Intercept Pharmaceuticals stocks from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
Is it a good time to buy Intercept Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Intercept Pharmaceuticals price performance over time
|1 week (2023-01-23)||15.65%|
|1 month (2022-12-30)||48.75%|
|3 months (2022-10-28)||28.40%|
|6 months (2022-07-29)||44.20%|
|1 year (2022-01-27)||27.42%|
|2 years (2021-01-29)||-47.79%|
|3 years (2020-01-30)||92.28|
|5 years (2018-01-30)||67.08|
Intercept Pharmaceuticals financials
|Revenue TTM||$379.8 million|
|Gross profit TTM||$360.4 million|
|Return on assets TTM||-3.94%|
|Return on equity TTM||0%|
|Market capitalisation||$671.8 million|
TTM: trailing 12 months
Intercept Pharmaceuticals share dividends
We're not expecting Intercept Pharmaceuticals to pay a dividend over the next 12 months.
Intercept Pharmaceuticals share price volatility
Over the last 12 months, Intercept Pharmaceuticals's shares have ranged in value from as little as $10.81 up to $21.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Intercept Pharmaceuticals's is 1.173. This would suggest that Intercept Pharmaceuticals's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Intercept Pharmaceuticals overview
Intercept Pharmaceuticals, Inc. , a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors.
Intercept Pharmaceuticals in the news
Intercept Surges To Four-Month High After Staving Off Amneal's Generic For 11 Years
Does Intercept (ICPT) Have the Potential to Rally 52.08% as Wall Street Analysts Expect?
Intercept's (ICPT) NDA for NASH Treatment Accepted By FDA
Frequently asked questionsWhat percentage of Intercept Pharmaceuticals is owned by insiders or institutions?
Currently 3.147% of Intercept Pharmaceuticals shares are held by insiders and 81.253% by institutions. How many people work for Intercept Pharmaceuticals?
Latest data suggests 437 work at Intercept Pharmaceuticals. When does the fiscal year end for Intercept Pharmaceuticals?
Intercept Pharmaceuticals's fiscal year ends in December. Where is Intercept Pharmaceuticals based?
Intercept Pharmaceuticals's address is: 10 Hudson Yards, New York, NY, United States, 10001 What is Intercept Pharmaceuticals's ISIN number?
Intercept Pharmaceuticals's international securities identification number is: US45845P1084 What is Intercept Pharmaceuticals's CUSIP number?
Intercept Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 45845P108
More guides on Finder
How to buy Neuraxis (NRXS) stock when it goes public
Everything we know about the Neuraxis IPO, plus information on how to buy in.
How to buy TXO Energy (TXO) stock
Everything we know about the TXO Energy IPO, plus information on how to buy in.
How to buy Brera (BREA) stock
Everything we know about the Brera IPO, plus information on how to buy in.
How to invest in the S&P 500
What you need to know about investing in the leading indicator for the overall US stock market.
How to buy IPO stock
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
How to buy Novo Integrated Sciences stock
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
How do ETFs work?
Your simple and straightforward guide to ETFs, how they work and the different types available.
What is stock lending?
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
How to buy SONDORS (SODR) stock when it goes public
Everything we know about the SONDORS IPO, plus information on how to buy in.
How to buy Bullfrog AI Holdings (BFRG) stock when it goes public
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Ask an Expert